Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs GE Vernova Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while GE Vernova Inc trades at $925.26 (market cap $267.41B). The key difference: GE Vernova Inc is far larger — about 8.6× GE HealthCare Technologies Inc. Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays the higher dividend (0.23%). Which is the better fit depends on your goals.
| GEHC | GEV | |
|---|---|---|
Market Cap | $31.07B | $267.41B |
Volume | 3,443,020 | 1,900,074 |
Sector | Health | Industrials |
52-Week High | $88.16 | $1.17K |
52-Week Low | $59.48 | $547.96 |
Enterprise Value | $39.53B | $257.08B |
Dividend Yield | 0.23% | 0.2% |
Typical Hold Time | — | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.
The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
